scholarly journals Modulation of bladder function by luminal adenosine turnover and A1 receptor activation

2012 ◽  
Vol 303 (2) ◽  
pp. F279-F292 ◽  
Author(s):  
H. Sandeep Prakasam ◽  
Heather Herrington ◽  
James R. Roppolo ◽  
Edwin K. Jackson ◽  
Gerard Apodaca

The bladder uroepithelium transmits information to the underlying nervous and musculature systems, is under constant cyclical strain, expresses all four adenosine receptors (A1, A2A, A2B, and A3), and is a site of adenosine production. Although adenosine has a well-described protective effect in several organs, there is a lack of information about adenosine turnover in the uroepithelium or whether altering luminal adenosine concentrations impacts bladder function or overactivity. We observed that the concentration of extracellular adenosine at the mucosal surface of the uroepithelium was regulated by ecto-adenosine deaminase and by equilibrative nucleoside transporters, whereas adenosine kinase and equilibrative nucleoside transporters modulated serosal levels. We further observed that enriching endogenous adenosine by blocking its routes of metabolism or direct activation of mucosal A1 receptors with 2-chloro- N6-cyclopentyladenosine (CCPA), a selective agonist, stimulated bladder activity by lowering the threshold pressure for voiding. Finally, CCPA did not quell bladder hyperactivity in animals with acute cyclophosphamide-induced cystitis but instead exacerbated their irritated bladder phenotype. In conclusion, we find that adenosine levels at both surfaces of the uroepithelium are modulated by turnover, that blocking these pathways or stimulating A1 receptors directly at the luminal surface promotes bladder contractions, and that adenosine further stimulates voiding in animals with cyclophosphamide-induced cystitis.

2017 ◽  
Vol 313 (2) ◽  
pp. F388-F403 ◽  
Author(s):  
Isabel Silva ◽  
Ana Filipa Costa ◽  
Sílvia Moreira ◽  
Fátima Ferreirinha ◽  
Maria Teresa Magalhães-Cardoso ◽  
...  

The direct detrusor relaxant effect of β3-adrenoceptor agonists as a primary mechanism to improve overactive bladder symptoms has been questioned. Among other targets, activation of β3-adrenoceptors downmodulate nerve-evoked acetylcholine (ACh) release, but there is insufficient evidence for the presence of these receptors on bladder cholinergic nerve terminals. Our hypothesis is that adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a retrograde messenger via prejunctional A1 receptors to explain inhibition of cholinergic activity by β3-adrenoceptors. Isoprenaline (1 µM) decreased [3H]ACh release from stimulated (10 Hz, 200 pulses) human (−47 ± 5%) and rat (−38 ± 1%) detrusor strips. Mirabegron (0.1 µM, −53 ± 8%) and CL316,243 (1 µM, −37 ± 7%) mimicked isoprenaline (1 µM) inhibition, and their effects were prevented by blocking β3-adrenoceptors with L748,337 (30 nM) and SR59230A (100 nM), respectively, in human and rat detrusor. Mirabegron and isoprenaline increased extracellular adenosine in the detrusor. Blockage of A1 receptors with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM) or the equilibrative nucleoside transporters (ENT) with dipyridamole (0.5 µM) prevented mirabegron and isoprenaline inhibitory effects. Dipyridamole prevented isoprenaline-induced adenosine outflow from the rat detrusor, and this effect was mimicked by the ENT1 inhibitor, S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM). Cystometry recordings in anesthetized rats demonstrated that SR59230A, DPCPX, dipyridamole, and NBTI reversed the decrease in the voiding frequency caused by isoprenaline (0.1–1,000 nM). Data suggest that inhibition of cholinergic neurotransmission by β3-adrenoceptors results from adenosine release via equilibrative nucleoside transporters and prejunctional A1-receptor stimulation in human and rat urinary bladder.


2020 ◽  
Vol 21 (3) ◽  
pp. 814 ◽  
Author(s):  
Kornkamon Lertsuwan ◽  
Supathra Phoaubon ◽  
Nathapol Tasnawijitwong ◽  
Jomnarong Lertsuwan

Cholangiocarcinoma (CCA) is a lethal disease with increasing incidence worldwide. Previous study showed that CCA was sensitive to adenosine. Thereby, molecular mechanisms of CCA inhibition by adenosine were examined in this study. Our results showed that adenosine inhibited CCA cells via an uptake of adenosine through equilibrative nucleoside transporters (ENTs), instead of activation of adenosine receptors. The inhibition of ENTs by NBTI caused the inhibitory effect of adenosine to subside, while adenosine receptor antagonists, caffeine and CGS-15943, failed to do so. Intracellular adenosine level was increased after adenosine treatment. Also, a conversion of adenosine to AMP by adenosine kinase is required in this inhibition. On the other hand, inosine, which is a metabolic product of adenosine has very little inhibitory effect on CCA cells. This indicates that a conversion of adenosine to inosine may reduce adenosine inhibitory effect. Furthermore, there was no specific correlation between level of proinflammatory proteins and CCA responses to adenosine. A metabolic stable analog of adenosine, 2Cl-adenosine, exerted higher inhibition on CCA cell growth. The disturbance in intracellular AMP level also led to an activation of 5′ AMP-activated protein kinase (AMPK). Accordingly, we proposed a novel adenosine-mediated cancer cell growth and invasion suppression via a receptor-independent mechanism in CCA.


2021 ◽  
Vol 2021 (3) ◽  
Author(s):  
Detlev Boison

A multifunctional, ubiquitous molecule, adenosine acts at cell-surface G protein-coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Extracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto-5’-nucleotidase activity (also producing inorganic phosphate). It is inactivated either by extracellular metabolism via adenosine deaminase (also producing ammonia) or, following uptake by nucleoside transporters, via adenosine deaminase or adenosine kinase (requiring ATP as co-substrate). Intracellular adenosine may be produced by cytosolic 5’-nucleotidases or through S-adenosylhomocysteine hydrolase (also producing L-homocysteine).


2012 ◽  
Vol 111 (suppl_1) ◽  
Author(s):  
Elodie Robin ◽  
Jessica Sabourin ◽  
Eric Raddatz

We previously established that exogenous adenosine (ADO) induces transient arrhythmias in the developing heart via the ADO A1 receptor (A1AR) and downstream activation of NADPH oxidase/ERK and PLC/PKC pathways. We assessed the hypothesis that both endogenous ADO and its derived compound inosine (INO) can simultaneously act in an autocrine/paracrine manner and induce rhythm and conduction disturbances. The validated model of the spontaneously beating heart obtained from 4-day-old chick embryos was used. The basal ADO/INO ratio determined by HPLC was approximately 10. Blockade of Equilibrative Nucleoside Transporters (ENTs) by dipyridamole, which is known to increase interstitial ADO level, induced transient atrial dysrhythmias and atrio-ventricular blocks in 70% of the hearts (n=30) and, in parallel, increased ERK2 phosphorylation. When extracellular conversion of AMP to ADO by ecto-5’-nucleotidase/CD73 was inhibited by AOPCP, the dipyridamole-induced arrhythmias were prevented. The dipyridamole-induced arrhythmias and ERK2 phosphorylation were prevented by the specific antagonist of the A1AR (DPCPX) but not by antagonists of A2AAR ( SCH58261 ), A2BAR (MRS1754) or A3AR (MRS1523). Interestingly, inhibition by EHNA of the conversion of ADO to INO by adenosine deaminase was not proarrhythmic whereas exogenous INO (500 µM) induced arrhythmias which were prevented by DPCPX. In conclusion, these findings suggest that endogenous ADO and INO in the interstitial compartment of the developing heart can provoke transient pacemaking and conduction disturbances via A1AR and downstream ERK activation in an autocrine/paracrine manner. Overall, our results provide new insights into the mechanisms underlying cardiac dysfunction when a hypoxic-ischemic episode induces local overproduction of ADO and INO


2019 ◽  
Vol 2019 (4) ◽  
Author(s):  
Detlev Boison

A multifunctional, ubiquitous molecule, adenosine acts at cell-surface G protein-coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Extracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto-5’-nucleotidase activity (also producing inorganic phosphate). It is inactivated either by extracellular metabolism via adenosine deaminase (also producing ammonia) or, following uptake by nucleoside transporters, via adenosine deaminase or adenosine kinase (requiring ATP as co-substrate). Intracellular adenosine may be produced by cytosolic 5’-nucleotidases or through S-adenosylhomocysteine hydrolase (also producing L-homocysteine).


2021 ◽  
Vol 9 (4) ◽  
Author(s):  
Siennah R. Miller ◽  
Joseph L. Jilek ◽  
Meghan E. McGrath ◽  
Raymond K. Hau ◽  
Erin Q. Jennings ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document